01 — At a Glance
The CDMO That Forgot the “D” Stood for Dependable
- Q3 FY26 Revenue₹494 Cr
- Q3 FY26 EBITDA₹83 Cr
- Q3 FY26 PAT₹(5.9) Cr
- TTM Profit Growth-66.4%
- 9M FY26 Revenue₹1,193 Cr
- 3-Year Sales CAGR-1.44%
- Book Value/Share₹96.9
- Debt/Equity0.57x
- Return on Equity (LY)7.38%
- Dividend Yield0.84%
Flash Summary: Hikal is a contract pharmaceutical and agrochemical ingredients manufacturer. Q3 FY26 saw revenue of ₹494 crore and EBITDA margin recovery to 16.8%, but the PAT came in at negative ₹5.9 crore because the US FDA warning letter made August 2025 feel like the financial markets version of a monsoon disaster. The stock has crashed 60% in a year. The company says the worst is behind. The balance sheet says “we’re still bleeding.” And the PE ratio of 81.4x is mathematically lying to you.
02 — Introduction
The Unlucky CDMO That Supplies Medicines Nobody Knows But Everyone Takes
Welcome to Hikal Limited, a company so unglamorous that it probably never gets invited to the Dalal Street parties where fund managers discuss multibaggers. Yet this Bengaluru-based manufacturer sits in one of the most critical supply chains on Earth: it makes active pharmaceutical ingredients (APIs) and crop protection chemicals that end up in medicines and pesticides globally.
The business model looks pristine on paper. Hikal manufactures for global pharma giants, crop protection companies, and specialized chemical players. They have FDA-approved plants in Bangalore, Panoli (Gujarat), and manufacturing sites in Taloja and Mahad (Maharashtra). The company was doing fine until August 2025 happened.
On August 21, 2025, the US FDA issued a warning letter to Hikal’s Jigani facility in Bangalore. This wasn’t a “here’s a friendly suggestion” letter. This was a “stop manufacturing for export to the United States immediately” warning. That single letter nuked the company’s growth prospects for the next two years, shattered investor confidence, and sent the stock from ₹457 to ₹165 — a 64% evaporation of shareholder value. The Q3 results show management’s “operational inflection” narrative — but numbers rarely lie. They just whisper uncomfortable truths.
From the Concall (Feb 2026): Management says “the worst is definitely behind us” and frames Q3 as “a positive turning point.” They’re expecting “double-digit pharma growth starting FY27.” They’ve also cut FY26 capex guidance from ₹200 crore to ₹150 crore. The message: batten down the hatches, remediate, then resurrect. The market’s response: thanks, but we need proof first.
03 — Business Model: WTF Do They Even Do?
Hikal Makes the Invisible Ingredients That Make the Visible Drugs Work
Members get full access to every article.
